US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Serina Therapeutics, Inc.

3.54

+0.820030.15%

Post-market: 3.32-0.2200-6.21%19:59 EST

Volume:66.37M

Turnover:274.22M

Market Cap:37.75M

PE:-1.99

High:4.08

Open:3.84

Low:3.41

Close:2.72

52wk High:7.92

52wk Low:1.71

Shares:10.66M

Float Shares:5.19M

Volume Ratio:43.64

T/O Rate:1277.92%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7830

EPS(LYR):-1.5139

ROE:-485.36%

ROA:-137.85%

PB:-11.87

PE(LYR):-2.34

Loading ...

Overview Company News Filings

Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares

Serina Therapeutics Says US FDA Places Clinical Hold On SER-252 Program

Serina Therapeutics posts $4.6 million net loss for third quarter 2025

Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares

Serina Therapeutics Inc. held annual shareholder meeting

Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Sale of Common Shares

BRIEF-Serina Therapeutics Says US FDA Places Clinical Hold On SER-252 Program

FDA Places Clinical Hold on Serina Therapeutics' SER-252 Parkinson's Drug Trial

Serina Therapeutics Inc - FDA Requests Additional Information on Excipient in Formulation

THOMSON REUTERS

Serina Therapeutics Inc - FDA Places Clinical Hold on Serina's Ser-252 Ind Application

THOMSON REUTERS

Serina Therapeutics Provides Regulatory Update on Ser-252 Program

THOMSON REUTERS

Chief Scientific Officer Randall Moreadith Reports Sale of Serina Therapeutics Inc. Common Shares

Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares

Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares

BRIEF-Serina Therapeutics Says Submits IND To FDA, Receives HREC Approval In Australia For SER-252- SEC Filing

Serina Therapeutics Inc - Submits Ind to FDA, Receives Hrec Approval in Australia for Ser-252 - SEC Filing

THOMSON REUTERS

Serina Therapeutics Secures $5 Million Funding Tranche and Gains Regulatory Approvals to Launch Global Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Serina Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting

Seres Therapeutics announces further constructive feedback from FDA on SER-155

Serina Therapeutics Inc. Announces Date for Virtual Annual Stockholders Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SER/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SER","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SER\",,,,,undefined,":{"symbol":"SER","market":"US","secType":"STK","nameCN":"Serina Therapeutics, Inc.","latestPrice":3.54,"timestamp":1769720400000,"preClose":2.72,"halted":0,"volume":66372909,"hourTrading":{"tag":"盘后","latestPrice":3.32,"preClose":3.54,"latestTime":"19:59 EST","volume":512974,"amount":1739808.666,"timestamp":1769734782615,"change":-0.22,"changeRate":-0.062147,"amplitude":0.110169},"delay":0,"changeRate":0.30147058823529405,"floatShares":5193821,"shares":10664064,"eps":-1.783,"marketStatus":"Not Yet Opened","change":0.82,"latestTime":"01-29 16:00:00 EST","open":3.84,"high":4.08,"low":3.41,"amount":274223675.81991273,"amplitude":0.246324,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.783,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769763600000},"marketStatusCode":0,"adr":0,"exchange":"AMEX","adjPreClose":2.72,"preHourTrading":{"tag":"盘前","latestPrice":3.81,"preClose":2.72,"latestTime":"09:29 EST","volume":12585515,"amount":54334625.851025,"timestamp":1769696999999,"change":1.09,"changeRate":0.400735,"amplitude":0.625},"postHourTrading":{"tag":"盘后","latestPrice":3.32,"preClose":3.54,"latestTime":"19:59 EST","volume":512974,"amount":1739808.666,"timestamp":1769734782615,"change":-0.22,"changeRate":-0.062147,"amplitude":0.110169},"volumeRatio":43.640083},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SER\",,,,,undefined,":{"symbol":"SER","floatShares":5193821,"roa":"-137.85%","roe":"-485.36%","lyrEps":-1.513928,"volumeRatio":43.640083,"shares":10664064,"dividePrice":0,"high":4.08,"amplitude":0.246324,"preClose":2.72,"low":3.41,"week52Low":1.7101,"pbRate":"-11.87","psRate":"325.44","week52High":7.92,"institutionHeld":0,"latestPrice":3.54,"eps":-1.783,"divideRate":0,"volume":66372909,"delay":0,"ttmEps":-1.783,"open":3.84,"prevYearClose":1.913,"prevWeekClose":2.87,"prevMonthClose":1.913,"prevQuarterClose":1.913,"fiveDayClose":2.96,"twentyDayClose":2.011,"sixtyDayClose":5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SER\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"SER","fiscalQuarterEnding":"2025/09","expectedEps":-0.47,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2025-08-11","symbol":"SER","fiscalQuarterEnding":"2025/06","expectedEps":-0.36,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-03-24","symbol":"SER","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2024-11-12","symbol":"SER","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":0.13},{"market":"US","date":"2024-08-09","symbol":"SER","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"post","actualEps":0.51}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SER\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SER\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1752469200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SER\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SER","date":"2026-01-28","current":-1.985418,"percent":0.865909,"low":-65.600015,"twenty":-12.310713,"median":-6.032011,"eighty":-3.272364,"high":37.356482,"avg":-11.959424,"sd":21.341143,"marketCap":29219535},"quantilePoints":[{"date":"2024-04-05","current":29.141387,"twenty":30.584579,"median":32.083279,"eighty":33.732959,"marketCap":105541506},{"date":"2024-04-12","current":17.770243,"twenty":17.783016,"median":23.543628,"eighty":32.232039,"marketCap":93646584},{"date":"2024-04-19","current":17.456349,"twenty":17.731924,"median":17.945869,"eighty":31.172957,"marketCap":91992413},{"date":"2024-04-26","current":14.673941,"twenty":16.787882,"median":17.778226,"eighty":29.502185,"marketCap":77329529},{"date":"2024-05-03","current":14.209648,"twenty":14.673941,"median":17.57865,"eighty":21.283439,"marketCap":74882770},{"date":"2024-05-10","current":14.050147,"twenty":14.209648,"median":17.078432,"eighty":18.800885,"marketCap":74042223},{"date":"2024-05-17","current":12.820759,"twenty":14.187327,"median":15.966076,"eighty":18.090969,"marketCap":67563528},{"date":"2024-05-24","current":15.167772,"twenty":14.187327,"median":15.718602,"eighty":17.818141,"marketCap":79931945},{"date":"2024-05-31","current":-13.721878,"twenty":13.545619,"median":15.079879,"eighty":17.786209,"marketCap":79931945},{"date":"2024-06-07","current":-14.08298,"twenty":12.926135,"median":14.744671,"eighty":17.776629,"marketCap":82035417},{"date":"2024-06-14","current":-14.564515,"twenty":-13.557216,"median":14.673941,"eighty":17.770243,"marketCap":84840426},{"date":"2024-06-21","current":-15.922863,"twenty":-13.825876,"median":14.209648,"eighty":17.731924,"marketCap":92753004},{"date":"2024-06-28","current":-12.919404,"twenty":-13.944317,"median":14.209648,"eighty":17.655287,"marketCap":75257414},{"date":"2024-07-05","current":-11.364849,"twenty":-13.990538,"median":14.209648,"eighty":17.52973,"marketCap":66201907},{"date":"2024-07-12","current":-11.153551,"twenty":-13.799876,"median":13.810656,"eighty":17.339222,"marketCap":64971062},{"date":"2024-07-15","current":-13.477836,"twenty":-13.773877,"median":13.571165,"eighty":17.280659,"marketCap":78510363},{"date":"2024-08-02","current":-12.964682,"twenty":-13.747877,"median":13.539233,"eighty":17.222095,"marketCap":75521166},{"date":"2024-08-09","current":-11.364095,"twenty":-13.723872,"median":13.251843,"eighty":17.027373,"marketCap":66197511},{"date":"2024-08-16","current":-8.441425,"twenty":-13.721878,"median":2.384851,"eighty":16.171527,"marketCap":59150297},{"date":"2024-08-23","current":-10.330099,"twenty":-13.617881,"median":-8.582039,"eighty":15.966076,"marketCap":72384510},{"date":"2024-08-30","current":-10.13985,"twenty":-13.52255,"median":-9.00413,"eighty":15.966076,"marketCap":71051408},{"date":"2024-09-06","current":-10.104487,"twenty":-13.488788,"median":-9.975078,"eighty":15.85112,"marketCap":70803616},{"date":"2024-09-13","current":-7.831133,"twenty":-13.268937,"median":-9.379361,"eighty":15.707426,"marketCap":54873890},{"date":"2024-09-20","current":-7.554188,"twenty":-13.112179,"median":-8.839249,"eighty":15.365752,"marketCap":52933298},{"date":"2024-09-27","current":-9.43006,"twenty":-13.019016,"median":-9.049816,"eighty":15.0623,"marketCap":66077809},{"date":"2024-10-04","current":-8.251303,"twenty":-12.937515,"median":-8.845695,"eighty":14.905865,"marketCap":57818083},{"date":"2024-10-11","current":-8.580848,"twenty":-12.554189,"median":-8.732946,"eighty":14.786183,"marketCap":60127254},{"date":"2024-10-18","current":-9.769745,"twenty":-12.214089,"median":-8.764633,"eighty":14.702233,"marketCap":68458031},{"date":"2024-10-25","current":-8.872369,"twenty":-11.941393,"median":-8.872369,"eighty":14.673941,"marketCap":62169982},{"date":"2024-10-31","current":-8.568173,"twenty":-11.747964,"median":-8.847019,"eighty":14.628789,"marketCap":60038439},{"date":"2024-11-08","current":-5.742165,"twenty":-11.5456,"median":-8.764633,"eighty":14.420496,"marketCap":40236191},{"date":"2024-11-15","current":-6.048407,"twenty":-11.364849,"median":-8.720054,"eighty":14.209648,"marketCap":44459880},{"date":"2024-11-22","current":-5.928673,"twenty":-11.364547,"median":-8.695365,"eighty":14.209648,"marketCap":43570682},{"date":"2024-11-29","current":-6.352149,"twenty":-11.321986,"median":-8.600455,"eighty":14.209648,"marketCap":46682874},{"date":"2024-12-06","current":-7.456945,"twenty":-11.110513,"median":-8.568173,"eighty":14.187327,"marketCap":54802179},{"date":"2024-12-13","current":-6.006451,"twenty":-10.914992,"median":-8.561836,"eighty":14.088465,"marketCap":44142287},{"date":"2024-12-20","current":-7.07266,"twenty":-10.789111,"median":-8.479449,"eighty":13.954351,"marketCap":51978012},{"date":"2024-12-27","current":-6.747673,"twenty":-10.659517,"median":-8.390726,"eighty":13.571165,"marketCap":49589633},{"date":"2025-01-03","current":-6.517639,"twenty":-10.562175,"median":-8.162579,"eighty":13.520073,"marketCap":47899077},{"date":"2025-01-10","current":-5.904214,"twenty":-10.499761,"median":-8.051056,"eighty":13.363605,"marketCap":43390929},{"date":"2025-01-17","current":-6.07035,"twenty":-10.463782,"median":-7.83254,"eighty":13.258229,"marketCap":44611886},{"date":"2025-01-24","current":-6.006451,"twenty":-10.451708,"median":-7.712623,"eighty":13.14966,"marketCap":44142287},{"date":"2025-01-31","current":-5.878654,"twenty":-10.421318,"median":-7.617562,"eighty":12.926135,"marketCap":43203089},{"date":"2025-02-07","current":-5.878654,"twenty":-10.364245,"median":-7.402632,"eighty":5.571028,"marketCap":43203089},{"date":"2025-02-14","current":-5.955332,"twenty":-10.299629,"median":-7.207741,"eighty":-5.38422,"marketCap":43766608},{"date":"2025-02-21","current":-6.249265,"twenty":-10.231108,"median":-7.041606,"eighty":-5.510713,"marketCap":45926762},{"date":"2025-02-28","current":-6.380056,"twenty":-10.13985,"median":-6.713492,"eighty":-5.574659,"marketCap":46887966},{"date":"2025-03-07","current":-6.326216,"twenty":-10.13478,"median":-6.696682,"eighty":-5.743169,"marketCap":46492287},{"date":"2025-03-14","current":-5.532074,"twenty":-10.112497,"median":-6.684888,"eighty":-5.743169,"marketCap":40656021},{"date":"2025-03-21","current":-6.110856,"twenty":-10.104487,"median":-6.616553,"eighty":-5.743169,"marketCap":44909571},{"date":"2025-03-28","current":-4.234631,"twenty":-10.098885,"median":-6.511249,"eighty":-5.532216,"marketCap":47178021},{"date":"2025-04-04","current":-4.894342,"twenty":-10.073941,"median":-6.460817,"eighty":-4.926436,"marketCap":54527860},{"date":"2025-04-11","current":-4.279206,"twenty":-10.051126,"median":-6.404799,"eighty":-4.716041,"marketCap":47674632},{"date":"2025-04-17","current":-4.680381,"twenty":-10.000427,"median":-6.391338,"eighty":-4.680381,"marketCap":52144128},{"date":"2025-04-25","current":-5.429242,"twenty":-9.949728,"median":-6.352149,"eighty":-4.680381,"marketCap":60487189},{"date":"2025-05-02","current":-4.733871,"twenty":-9.769745,"median":-6.319486,"eighty":-4.680381,"marketCap":52740061},{"date":"2025-05-09","current":-5.121942,"twenty":-9.696231,"median":-6.287604,"eighty":-4.698211,"marketCap":57063554},{"date":"2025-05-16","current":-59.867974,"twenty":-10.063801,"median":-6.319486,"eighty":-4.716041,"marketCap":56216028},{"date":"2025-05-23","current":-62.521698,"twenty":-10.1145,"median":-6.352149,"eighty":-4.716041,"marketCap":58707874},{"date":"2025-05-30","current":-61.035612,"twenty":-10.269158,"median":-6.380056,"eighty":-4.730305,"marketCap":57312440},{"date":"2025-06-06","current":-63.15859,"twenty":-10.460251,"median":-6.404799,"eighty":-4.739577,"marketCap":59305916},{"date":"2025-06-13","current":-62.893218,"twenty":-10.844881,"median":-6.460817,"eighty":-4.756693,"marketCap":59056732},{"date":"2025-06-20","current":-61.035612,"twenty":-11.364397,"median":-6.504859,"eighty":-4.787361,"marketCap":57312440},{"date":"2025-06-27","current":-65.069271,"twenty":-11.941393,"median":-6.601297,"eighty":-4.858682,"marketCap":61100045},{"date":"2025-07-03","current":-63.052442,"twenty":-12.946571,"median":-6.683774,"eighty":-4.897908,"marketCap":59206243},{"date":"2025-07-11","current":-62.585387,"twenty":-13.494265,"median":-6.687561,"eighty":-4.963879,"marketCap":58767678},{"date":"2025-07-18","current":-56.365062,"twenty":-13.727859,"median":-6.706215,"eighty":-5.054812,"marketCap":52926793},{"date":"2025-07-25","current":-57.320401,"twenty":-14.163867,"median":-6.747673,"eighty":-5.06551,"marketCap":53823857},{"date":"2025-08-01","current":-58.806486,"twenty":-14.540367,"median":-7.140201,"eighty":-5.097711,"marketCap":55219290},{"date":"2025-08-08","current":-57.851146,"twenty":-16.339423,"median":-7.348318,"eighty":-5.123618,"marketCap":54322226},{"date":"2025-08-15","current":-4.477661,"twenty":-17.151414,"median":-7.290809,"eighty":-5.06551,"marketCap":56378234},{"date":"2025-08-22","current":-4.477661,"twenty":-16.339423,"median":-7.07266,"eighty":-4.840851,"marketCap":56378234},{"date":"2025-08-29","current":-4.176437,"twenty":-15.621008,"median":-6.732661,"eighty":-4.723173,"marketCap":52585516},{"date":"2025-09-05","current":-4.298555,"twenty":-15.168225,"median":-6.706215,"eighty":-4.683947,"marketCap":54123104},{"date":"2025-09-12","current":-4.152013,"twenty":-15.047483,"median":-6.687561,"eighty":-4.603418,"marketCap":52277998},{"date":"2025-09-19","current":-3.671682,"twenty":-14.552441,"median":-6.683774,"eighty":-4.480762,"marketCap":46230151},{"date":"2025-09-26","current":-4.054319,"twenty":-14.495088,"median":-6.586042,"eighty":-4.445795,"marketCap":51047928},{"date":"2025-10-03","current":-4.274131,"twenty":-14.455909,"median":-6.482838,"eighty":-4.363684,"marketCap":53815587},{"date":"2025-10-10","current":-4.670023,"twenty":-14.397862,"median":-6.433897,"eighty":-4.347636,"marketCap":58800259},{"date":"2025-10-17","current":-4.092547,"twenty":-14.188422,"median":-6.402621,"eighty":-4.323139,"marketCap":51529260},{"date":"2025-10-24","current":-4.322701,"twenty":-14.088758,"median":-6.364249,"eighty":-4.310147,"marketCap":54427122},{"date":"2025-10-31","current":-4.008855,"twenty":-14.036759,"median":-6.339182,"eighty":-4.297619,"marketCap":50475491},{"date":"2025-11-07","current":-3.448117,"twenty":-13.827869,"median":-6.299296,"eighty":-4.264361,"marketCap":43415245},{"date":"2025-11-14","current":-3.280733,"twenty":-13.729853,"median":-6.273601,"eighty":-4.236343,"marketCap":41307709},{"date":"2025-11-21","current":-2.15737,"twenty":-13.721878,"median":-6.249265,"eighty":-4.197811,"marketCap":40096880},{"date":"2025-11-28","current":-2.444254,"twenty":-13.721878,"median":-6.245456,"eighty":-4.152013,"marketCap":45428912},{"date":"2025-12-05","current":-1.990977,"twenty":-13.591882,"median":-6.147028,"eighty":-4.102049,"marketCap":37004302},{"date":"2025-12-12","current":-1.801633,"twenty":-13.505217,"median":-6.121468,"eighty":-4.090954,"marketCap":33485160},{"date":"2025-12-19","current":-1.524503,"twenty":-13.477836,"median":-6.11051,"eighty":-4.06246,"marketCap":28334418},{"date":"2025-12-26","current":-1.399995,"twenty":-13.199304,"median":-6.089519,"eighty":-4.041726,"marketCap":26020316},{"date":"2026-01-02","current":-1.097619,"twenty":-13.112179,"median":-6.083129,"eighty":-3.997732,"marketCap":20400354},{"date":"2026-01-09","current":-1.503274,"twenty":-13.019016,"median":-6.07035,"eighty":-3.774262,"marketCap":27939847},{"date":"2026-01-16","current":-1.543438,"twenty":-12.937515,"median":-6.048407,"eighty":-3.438074,"marketCap":28686332},{"date":"2026-01-23","current":-1.698355,"twenty":-12.675928,"median":-6.046598,"eighty":-3.349361,"marketCap":31565629},{"date":"2026-01-28","current":-1.572126,"twenty":-12.310713,"median":-6.032011,"eighty":-3.272364,"marketCap":29219535}],"updateTime":1769745017668},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SER\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584092040","title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584092040","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584092040?lang=en_us&edition=fundamental","pubTime":"2025-11-20 02:48","pubTimestamp":1763578093,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDLbJkQ3H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2584492582","title":"Serina Therapeutics Says US FDA Places Clinical Hold On SER-252 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2584492582","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584492582?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:25","pubTimestamp":1763569553,"startTime":"0","endTime":"0","summary":"Nov 3 (Reuters) - Serina Therapeutics Inc ::*SERINA THERAPEUTICS PROVIDES REGULATORY UPDATE ON SER-252 PROGRAM*SERINA THERAPEUTICS INC - FDA PLACES CLINICAL HOLD ON SERINA'S SER-252 IND APPLICATION*SE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD3TF4fy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2583569698","title":"Serina Therapeutics posts $4.6 million net loss for third quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583569698","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583569698?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:07","pubTimestamp":1763032051,"startTime":"0","endTime":"0","summary":"Serina Therapeutics Inc. reported operating expenses of $6.4 million for the third quarter ended September 30, 2025, up from $5.3 million in the same period of 2024. General and administrative expenses were $2.7 million, compared to $2.9 million in the prior year, mainly due to reduced compensation costs partially offset by increased investor outreach expenses. Other income was $1.8 million, down from $6.7 million last year, primarily due to changes in the fair value of liability classified warrants, partially offset by gains from warrant expirations. The company reported a net loss of $4.6 million, or $0.45 per basic and diluted share, compared to net income of $1.4 million, or $0.16 per basic share and $0.13 per diluted share, in 2024. During the quarter, Serina launched a new corporate communications platform and continued its at-the-market equity program, issuing 474,712 shares at an average price of $6.00, raising $2.8 million in net proceeds. The company also highlighted FDA alig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL4V6n4B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2583564309","title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583564309","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583564309?lang=en_us&edition=fundamental","pubTime":"2025-11-13 01:38","pubTimestamp":1762969133,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported the disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL2d5FgW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2583309550","title":"Serina Therapeutics Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2583309550","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583309550?lang=en_us&edition=fundamental","pubTime":"2025-11-13 01:37","pubTimestamp":1762969057,"startTime":"0","endTime":"0","summary":"Serina Therapeutics Inc. held its annual meeting of stockholders on November 7, 2025. Stockholders elected Steve Ledger and Karen J. Wilson to the board of directors. The appointment of Frazier & Deeter, LLC as the independent registered public accounting firm for the 2025 fiscal year was ratified. Stockholders also approved the issuance of common stock in connection with the exercise of the Convertible Note and Warrants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 12, 2025, and is solely responsible for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL9mf2Hn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2581706119","title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581706119","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581706119?lang=en_us&edition=fundamental","pubTime":"2025-11-06 04:30","pubTimestamp":1762374619,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL1m53Zt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2580292583","title":"BRIEF-Serina Therapeutics Says US FDA Places Clinical Hold On SER-252 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2580292583","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580292583?lang=en_us&edition=fundamental","pubTime":"2025-11-03 19:44","pubTimestamp":1762170270,"startTime":"0","endTime":"0","summary":"BRIEF-Serina Therapeutics Says US FDA Places Clinical Hold On SER-252 ProgramNov 3 (Reuters) - Serina Therapeutics Inc SER.A:SERINA THERAPEUTICS PROVIDES REGULATORY UPDATE ON SER-252 PROGRAMSERINA THE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA365RJN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2580596291","title":"FDA Places Clinical Hold on Serina Therapeutics' SER-252 Parkinson's Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2580596291","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580596291?lang=en_us&edition=fundamental","pubTime":"2025-11-03 19:05","pubTimestamp":1762167936,"startTime":"0","endTime":"0","summary":"Serina Therapeutics Inc. announced that the U.S. Food and Drug Administration  has placed a clinical hold on its Investigational New Drug  application for SER-252, the company's lead program for advanced Parkinson's disease. The FDA is requesting additional information regarding a commonly used excipient in the drug's formulation. The agency's feedback does not concern the active drug substance or its mechanism of action. Serina Therapeutics stated it will work quickly to address the FDA's requests and expects to receive a formal clinical-hold letter within 30 days. The company emphasized its commitment to advancing SER-252 and its broader drug development pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL3RZH5Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2580329137","title":"Serina Therapeutics Inc - FDA Requests Additional Information on Excipient in Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2580329137","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580329137?lang=en_us&edition=fundamental","pubTime":"2025-11-03 19:05","pubTimestamp":1762167900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA365RJN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2580322291","title":"Serina Therapeutics Inc - FDA Places Clinical Hold on Serina's Ser-252 Ind Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2580322291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580322291?lang=en_us&edition=fundamental","pubTime":"2025-11-03 19:05","pubTimestamp":1762167900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA365RJN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2580291351","title":"Serina Therapeutics Provides Regulatory Update on Ser-252 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2580291351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580291351?lang=en_us&edition=fundamental","pubTime":"2025-11-03 19:05","pubTimestamp":1762167900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA365RJN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2579967408","title":"Chief Scientific Officer Randall Moreadith Reports Sale of Serina Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2579967408","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579967408?lang=en_us&edition=fundamental","pubTime":"2025-10-29 01:23","pubTimestamp":1761672217,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL42QXtN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2577317870","title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2577317870","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577317870?lang=en_us&edition=fundamental","pubTime":"2025-10-22 00:25","pubTimestamp":1761063921,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL4Gfhdy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2575434462","title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2575434462","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575434462?lang=en_us&edition=fundamental","pubTime":"2025-10-15 01:17","pubTimestamp":1760462221,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., reported a disposal of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL9FdWqC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2573989327","title":"BRIEF-Serina Therapeutics Says Submits IND To FDA, Receives HREC Approval In Australia For SER-252- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2573989327","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573989327?lang=en_us&edition=fundamental","pubTime":"2025-10-07 05:58","pubTimestamp":1759787926,"startTime":"0","endTime":"0","summary":"BRIEF-Serina Therapeutics Says Submits IND To FDA, Receives HREC Approval In Australia For SER-252- SEC FilingOct 6  - Serina Therapeutics Inc SER.A:SERINA THERAPEUTICS INC - SUBMITS IND TO FDA, RECEIVES HREC APPROVAL IN AUSTRALIA FOR SER-252 - SEC FILINGSource text: [ID:n0001708599-25-000122]Further company coverage: SER.A ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nFWN3VN1DN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2573098565","title":"Serina Therapeutics Inc - Submits Ind to FDA, Receives Hrec Approval in Australia for Ser-252 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2573098565","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573098565?lang=en_us&edition=fundamental","pubTime":"2025-10-07 04:56","pubTimestamp":1759784161,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nFWN3VN1DN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2573988269","title":"Serina Therapeutics Secures $5 Million Funding Tranche and Gains Regulatory Approvals to Launch Global Registrational Trial of SER-252 for Advanced Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2573988269","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573988269?lang=en_us&edition=fundamental","pubTime":"2025-10-07 04:13","pubTimestamp":1759781605,"startTime":"0","endTime":"0","summary":"Serina Therapeutics Secures $5 Million Funding Tranche and Gains Regulatory Approvals to Launch Global Registrational Trial of SER-252 for Advanced Parkinson's Disease. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 06, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDLb7h01l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2570880496","title":"Serina Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2570880496","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570880496?lang=en_us&edition=fundamental","pubTime":"2025-09-26 23:30","pubTimestamp":1758900658,"startTime":"0","endTime":"0","summary":"Serina Therapeutics, Inc. has announced that it will hold its Annual Meeting of Stockholders on November 7, 2025. During the meeting, stockholders will vote on the election of Class II directors, the ratification of the appointment of independent registered public accountants, and the approval of the issuance of common stock in connection with the exercise of certain Convertible Note and Warrants. Other business may also be transacted as may properly come before the meeting or any adjournments thereof. The meeting will be held virtually.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDLGN90j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2569792580","title":"Seres Therapeutics announces further constructive feedback from FDA on SER-155","url":"https://stock-news.laohu8.com/highlight/detail?id=2569792580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569792580?lang=en_us&edition=fundamental","pubTime":"2025-09-23 19:05","pubTimestamp":1758625525,"startTime":"0","endTime":"0","summary":"Seres Therapeutics (MCRB) announced receipt of additional constructive feedback from the U.S. Food and Drug Administration, FDA, on the Phase 2 stu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/seres-therapeutics-announces-further-constructive-feedback-from-fda-on-ser-155-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/seres-therapeutics-announces-further-constructive-feedback-from-fda-on-ser-155-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MCRB","BK4139","SER"],"gpt_icon":0},{"id":"2567632140","title":"Serina Therapeutics Inc. Announces Date for Virtual Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2567632140","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567632140?lang=en_us&edition=fundamental","pubTime":"2025-09-16 05:07","pubTimestamp":1757970432,"startTime":"0","endTime":"0","summary":"Serina Therapeutics, Inc. has announced its Annual Meeting of Stockholders, scheduled to take place on November 7, 2025. During the meeting, stockholders will vote on the election of two Class II directors, with nominees including Steve Ledger.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL8BDngt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":59,"code":"91000000","status":"200"}]}}